The purpose of this study was to investigate the use of a radiolabeled mouse monoclonal antibody (and its F(ab′)2 fragment) against α-fetoprotein in the scinti-graphic diagnosis of hepatocellular carcinoma. Twenty-six southern African Blacks and one Caucasian with hepatocellular carcinoma and four patients with other malignant tumors of the liver were studied. Although six hepatocellular carcinomas appeared to selectively concentrate α-fetoprotein antibody, one of these tumors was not producing α-fetoprotein. Moreover, in another 18 patients with α-fetoprotein-producing hepatocellular carcinomas, uptake of α-fetoprotein antibody was at best only equal to that in nontumorous hepatic tissue, and three hepatocellular carcinomas that were not producing α-fetoprotein concentrated the antibody to the same extent as did the α-fetoprotein-producing tumors and hepatic tissue. All four tumors other than hepatocellular carcinoma concentrated α-fetoprotein antibody as well as did hepatic tissue. These findings suggest that the penetration of hepatocellular carcinomas by α-fetoprotein antibody is a passive and nonselective process. This conclusion is supported by an in vitro study in which a non-α-fetoprotein-producing hepatic metastasis took up as much radiolabeled α-fetoprotein antibody as did three of four α-fetoprotein-producing hepatocellular carcinomas. A likely explanation for the failure of α-fetoprotein monoclonal antibody to be selectively concentrated by hepatocellular carcinomas is that α-fetoprotein is an export protein and is not expressed on the cell membranes of malignant hepatocytes.

01 Aug 1980·Cancer research

Localization of radioiodinated antibody to alpha-fetoprotein in hepatoma transplanted in rats and a case report of alpha-fetoprotein antibody treatment of a hepatoma patient.

Article

Author: Nishi, S ; Tsukada, Y ; Ishii, N ; Koji, T ; Munehisa, T ; Kobayashi, K ; Tamenishi, A ; Hara, A ; Hirai, H ; Kusumoto, Y ; Nakamura, S

100 Deals associated with HE-317

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Autoimmune Diseases	Discovery	United States	Harbor Therapeutics, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

HE-317

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation